article thumbnail

New UK intracellular drug delivery centre to support RNA development

Pharmaceutical Technology

A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. The funding is being provided under the agency’s Transforming Medicines Manufacturing programme.

article thumbnail

Khosla Ventures’ Alex Morgan on biotech’s challenges and solving drug delivery

Bio Pharma Dive

The life sciences investor has backed a number of startups working on technologies for delivering and manufacturing cell and gene medicines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Orexo, leveraging drug delivery tech, seeks FDA approval of nasal high-dose opioid rescue medicine

Fierce Pharma

Orexo, leveraging drug delivery tech, seeks FDA approval of nasal high-dose opioid rescue medicine ntaylor Tue, 02/07/2023 - 08:18

article thumbnail

Unlocking the potential of mucoadhesive drug delivery

Drug Discovery World

Ashley Rein , Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. . Consider drug delivery systems early on .

article thumbnail

Injectable Drug Delivery 2022

pharmaphorum

There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years.

article thumbnail

Alkermes, continuing transformation, plans to split in two

Bio Pharma Dive

The biotech’s transition from drug delivery specialist to maker of novel medicines led to competing neuroscience and oncology divisions. The latter will soon become a separate company.

article thumbnail

RVAC Medicines, A*STAR partner for mRNA manufacturing expertise

Pharmaceutical Technology

RVAC Medicines has signed a master research partnership agreement with the Agency for Science, Technology and Research (A*STAR) for analysing and developing solutions to build messenger ribonucleic acid (mRNA) manufacturing and analytics expertise in Singapore. Topic sponsors are not involved in the creation of editorial content.